Published in Immunity on January 01, 2007
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood (2012) 2.39
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
E-selectin engages PSGL-1 and CD44 through a common signaling pathway to induce integrin alphaLbeta2-mediated slow leukocyte rolling. Blood (2010) 2.24
Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Clin Cancer Res (2015) 1.79
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer (2014) 1.76
B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol (2013) 1.72
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood (2013) 1.69
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov (2015) 1.67
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia (2014) 1.60
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood (2012) 1.45
Phospholipase C-mediated hydrolysis of PIP2 releases ERM proteins from lymphocyte membrane. J Cell Biol (2009) 1.41
B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol (2013) 1.39
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood (2017) 1.38
Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol Rev (2009) 1.32
A critical role of Rap1b in B-cell trafficking and marginal zone B-cell development. Blood (2008) 1.12
The calcium-activated nonselective cation channel TRPM4 is essential for the migration but not the maturation of dendritic cells. Nat Immunol (2008) 1.10
Characterization of phospholipase C gamma enzymes with gain-of-function mutations. J Biol Chem (2009) 1.09
Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res (2013) 1.02
Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood (2015) 1.01
Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci (2010) 0.99
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta (2015) 0.98
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood (2015) 0.98
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol (2014) 0.97
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol (2013) 0.95
BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia (2015) 0.95
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget (2014) 0.94
Conformational switching in ezrin regulates morphological and cytoskeletal changes required for B cell chemotaxis. J Immunol (2011) 0.92
Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol (2012) 0.92
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget (2015) 0.91
Reduced diabetes in btk-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene. J Immunol (2009) 0.89
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol (2014) 0.86
Stromal cell-derived factor-1 signaling via the CXCR4-TCR heterodimer requires phospholipase C-β3 and phospholipase C-γ1 for distinct cellular responses. J Immunol (2011) 0.86
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. Oncotarget (2015) 0.84
An essential role of the cytoplasmic tail of CXCR4 in G-protein signaling and organogenesis. PLoS One (2010) 0.84
Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res (2015) 0.84
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget (2016) 0.83
The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene (2013) 0.82
Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochem Soc Trans (2007) 0.81
Bruton's tyrosine kinase promotes persistence of mature anti-insulin B cells. J Immunol (2014) 0.81
Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res (2016) 0.80
B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. Immunotargets Ther (2014) 0.79
Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc. Cell Death Dis (2014) 0.79
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica (2011) 0.78
Quantitative analysis of B-lymphocyte migration directed by CXCL13. Integr Biol (Camb) (2016) 0.77
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. J Biol Chem (2016) 0.77
The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol (2016) 0.77
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia (2016) 0.77
Ibrutinib: a paradigm shift in management of CLL. Expert Rev Hematol (2014) 0.77
Transcriptome profiling of monocytes from XLA patients revealed the innate immune function dysregulation due to the BTK gene expression deficiency. Sci Rep (2017) 0.76
Rac-mediated Stimulation of Phospholipase Cγ2 Amplifies B Cell Receptor-induced Calcium Signaling. J Biol Chem (2015) 0.76
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. Oncotarget (2016) 0.75
Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types? Scientifica (Cairo) (2014) 0.75
BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia. Ann Hematol (2016) 0.75
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. Oncotarget (2016) 0.75
The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival. Oncoimmunology (2017) 0.75
CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol (2009) 5.87
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature (2011) 4.34
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest (2011) 4.21
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 4.17
GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol (2007) 2.49
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A (2004) 2.46
The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med (2003) 2.21
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res (2010) 2.12
A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med (2013) 1.87
Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell (2011) 1.80
Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res (2008) 1.79
Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res (2002) 1.78
A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet (2013) 1.73
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood (2013) 1.69
Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler Thromb Vasc Biol (2013) 1.64
P-selectin glycoprotein ligand-1 is expressed on endothelial cells and mediates monocyte adhesion to activated endothelium. Arterioscler Thromb Vasc Biol (2007) 1.63
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood (2002) 1.50
Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J Exp Med (2013) 1.42
B cell signaling and tumorigenesis. Annu Rev Immunol (2005) 1.40
ANKRD26-related thrombocytopenia and myeloid malignancies. Blood (2013) 1.32
Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med (2005) 1.32
Lymphoma dissemination: the other face of lymphocyte homing. Blood (2007) 1.31
Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol (2006) 1.26
Mutation of the mouse Rad17 gene leads to embryonic lethality and reveals a role in DNA damage-dependent recombination. EMBO J (2004) 1.22
Peyer's patch M cells derived from Lgr5(+) stem cells require SpiB and are induced by RankL in cultured "miniguts". Mol Cell Biol (2012) 1.21
miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest (2009) 1.16
Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood (2005) 1.16
MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. Hum Mutat (2013) 1.15
CD44 is a macrophage binding site for Mycobacterium tuberculosis that mediates macrophage recruitment and protective immunity against tuberculosis. J Clin Invest (2003) 1.15
Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. Eur J Biochem (2002) 1.13
Involvement of SLP-65 and Btk in tumor suppression and malignant transformation of pre-B cells. Semin Immunol (2005) 1.12
Primary follicular lymphoma of the small intestine: alpha4beta7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B cells. Am J Pathol (2003) 1.11
Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells. J Exp Med (2003) 1.10
Protection against renal ischemia reperfusion injury by CD44 disruption. J Am Soc Nephrol (2005) 1.10
The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity. Immunity (2012) 1.09
GATA-3 promotes T-cell specification by repressing B-cell potential in pro-T cells in mice. Blood (2013) 1.08
CD44 deficiency increases tubular damage but reduces renal fibrosis in obstructive nephropathy. J Am Soc Nephrol (2004) 1.08
MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol (2010) 1.05
Hypoxia induces netrin-1 and Unc5b in atherosclerotic plaques: mechanism for macrophage retention and survival. Arterioscler Thromb Vasc Biol (2013) 1.05
Urothelial CD44 facilitates Escherichia coli infection of the murine urinary tract. J Immunol (2006) 1.03
A subfraction of B220(+) cells in murine bone marrow and spleen does not belong to the B cell lineage but has dendritic cell characteristics. Eur J Immunol (2002) 1.03
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer (2010) 1.02
Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children. Pediatr Res (2002) 1.01
Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. Blood (2011) 1.01
IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood (2013) 1.00
Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol (2003) 0.99
Impaired hematopoiesis in mice lacking the transcription factor Sp3. Blood (2003) 0.99
Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood (2004) 0.99
Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int (2002) 0.98
Memory CD4(+)CCR5(+) T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. Blood (2012) 0.98
CD44 disruption prevents degeneration of the capillary network in obstructive nephropathy via reduction of TGF-beta1-induced apoptosis. J Am Soc Nephrol (2006) 0.98
Impaired precursor B cell differentiation in Bruton's tyrosine kinase-deficient mice. J Immunol (2002) 0.97
Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ Res (2013) 0.95
Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma. FEBS J (2013) 0.95
The pre-BCR checkpoint as a cell-autonomous proliferation switch. Trends Immunol (2004) 0.94
The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta (2010) 0.94
Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res (2008) 0.92
Hyaluronic acid metabolism is increased in unstable plaques. Eur J Clin Invest (2010) 0.92
c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol (2002) 0.92
Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PLoS One (2012) 0.91
GATA3 controls the expression of CD5 and the T cell receptor during CD4 T cell lineage development. Eur J Immunol (2007) 0.91
No evidence for an association of ocular adnexal lymphoma with Chlamydia psittaci in a cohort of patients from the Netherlands. Leuk Res (2006) 0.90
Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood (2009) 0.90
The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood (2008) 0.89
Human enteroids: preclinical models of non-inflammatory diarrhea. Stem Cell Res Ther (2013) 0.88
Intracerebral infiltration as the unique cause of the clinical presentation of chronic lymphocytic leukemia/small lymphocytic leukemia. J Clin Oncol (2011) 0.88
Impaired lymphoid organ development in mice lacking the heparan sulfate modifying enzyme glucuronyl C5-epimerase. J Immunol (2010) 0.87
Tubular epithelial syndecan-1 maintains renal function in murine ischemia/reperfusion and human transplantation. Kidney Int (2012) 0.87
CD44 expression in IgA nephropathy. Am J Kidney Dis (2002) 0.87
Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway. Blood (2009) 0.87
Endothelial CD81 is a marker of early human atherosclerotic plaques and facilitates monocyte adhesion. Cardiovasc Res (2008) 0.85
Stimulated plasmacytoid dendritic cells impair human T-cell development. Blood (2006) 0.85
Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity. Blood (2004) 0.85
Waxing and waning intravascular large cell lymphoma with widespread organ infiltration. Leuk Lymphoma (2010) 0.84
Bruton's tyrosine kinase and SLP-65 regulate pre-B cell differentiation and the induction of Ig light chain gene rearrangement. J Immunol (2006) 0.84